Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 42.9%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Psychophysical testing for recovery of sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

It is very uncertain whether systemic corticosteroids plus intranasal… changes psychophysical testing for recovery of sense of smell compared with no intervention (very low certainty).

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
RR 11 [0.7, 173.66]
1 study · 18 participants
Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Change in sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low